Patents Assigned to Genesis Group Inc.
-
Publication number: 20150216195Abstract: An improved apparatus for processing sea cucumbers having stages for orienting/aligning, cutting, splitting, flattening, eviscerating and cleaning the sea cucumber, and for collecting the eviscerated innards. A method for the automated splitting and evisceration of sea cucumbers using the apparatus of the present disclosure. A flattening plate and trough during the orienting/aligning step relax the sea cucumber and discourage its defence mechanisms. A wedge shaped flattening plate splits and flattens the sea cucumber immediately after the incision. Pronged discs maintain positioning of the sea cucumber during an aggressive wash and brush cleaning cycle, which may be repeated. Optionally, a vacuum may suction off a portion of the innards prior to cleaning.Type: ApplicationFiled: August 15, 2013Publication date: August 6, 2015Applicants: Marine Institute of Memorial University of Newfoundland, Canadian Centre for fisheries Innovation, Genesis Group Inc., Memorial University of NewfoundlandInventors: Joseph Singleton, Mark Ingerman, Stephen King
-
Patent number: 9018248Abstract: The present disclosure relates to fatty acid derivatives of green tea catechins including epicatechin (EC), epicatechin gallate (ECG), epigallocatechin (EGC), epigallocatechin gallate (EGCG) and their epimers (e.g., catechin, catechin gallate, gallocatechin, gallocatechin gallate) or their mixtures and/or green tea extracts.Type: GrantFiled: April 8, 2011Date of Patent: April 28, 2015Assignee: Genesis Group Inc.Inventors: Fereidoon Shahidi, Ying Zhong
-
Patent number: 8409799Abstract: Methods and compositions relating to diagnosing and treating cardiomyopathy and particularly relating to methods and compositions for diagnosing and treating arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) are described. Provided are methods for screening for, diagnosing or detecting a risk of developing arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) comprising detecting the presence of a transmembrane protein 43 (TMEM43) disease associated variant in a sample of a subject, wherein the presence of a TMEM43 disease variant is indicative that the subject has ARVD/C or an increased risk of developing ARVD/C compared to an individual having wild type TMEM43.Type: GrantFiled: December 19, 2008Date of Patent: April 2, 2013Assignee: Genesis Group Inc.Inventors: Terry-Lynn Young, Kathy Hodgkinson, Sean Connors, Patrick Parfrey, Annika Haywood, Nancy Merner, Vanessa French
-
Patent number: 8320666Abstract: A system and method implemented as a software tool for generating alpha matte sequences in real-time for the purposes of background or foreground substitution in digital images and video. The system and method is based on a set of modified Poisson equations that are derived for handling multichannel color vectors. Greater robustness is achieved by computing an initial alpha matte in color space. Real-time processing speed is achieved through optimizing the algorithm for parallel processing on the GPUs. For online video matting, a modified background cut algorithm is implemented to separate foreground and background, which guides the automatic trimap generation. Quantitative evaluation on still images shows that the alpha mattes extracted using the present invention has improved accuracy over existing state-of-the-art offline image matting techniques.Type: GrantFiled: August 13, 2010Date of Patent: November 27, 2012Assignee: Genesis Group Inc.Inventor: Minglun Gong
-
Patent number: 7635560Abstract: Expression of pygopus mRNA and Pygopus protein in established cancer cell lines and in patient tumors is described. Pygopus is shown to be a feasible diagnostic and prognostic indicator. Pygopus is also useful in cancer treatment therapy, for example in disrupting strategies that specifically target the activity of pygopus in cancer cells.Type: GrantFiled: April 16, 2004Date of Patent: December 22, 2009Assignee: Genesis Group Inc.Inventors: Kenneth Kao, Catherine Popadiuk
-
Patent number: 6904864Abstract: A control system to control the descent of a seafaring vessel, such as a lifeboat, into water is disclosed herein. The control system, and an accompanying method, control the descent speed of the seafaring vessel to minimise the possibility of setback after splashdown, and thus increase the probability of a safe and orderly launch.Type: GrantFiled: February 21, 2003Date of Patent: June 14, 2005Assignees: National Research Council of Canada, Genesis Group Inc.Inventors: Antonio Simões Ré, Terry Finch, Brian J. Vietch, Gregory Janes, Michael Sullivan, Edward Kennedy
-
Publication number: 20050026168Abstract: A method for determining whether an individual is at an increased risk for myocardial infarction, comprising screening for the presence of Factor II and Factor XIII alleles associated with myocardial infarction. Also provided are kits and primers that specifically hybridize adjacent to the allele-specific regions of the Factor II and Factor XIII genes.Type: ApplicationFiled: December 12, 2003Publication date: February 3, 2005Applicant: Genesis Group Inc.Inventor: Ya-Gang Xie
-
Patent number: 6792421Abstract: The present invention is directed to the use of linkcells in retrieving site data pertaining to one or more sites from a site data repository. The linkcells facilitate the resolution of several types of queries, including queries to determine a specified number of closest sites to a user's location and queries to determine sites located with a specified distance of the user's location. In one aspect, the present invention relates to a linkcell having a cell perimeter that comprises one or more cell boundary sections, a cell identifier, and a link to a data table, where one or more sites are associated with the linkcell, and where site data pertaining to those sites is stored in the data table. The cell identifier may be a name derived from the coordinates of sites associated with the linkcell. Advantageously, it is not typically necessary to examine data on all sites in the site data repository to resolve queries if linkcells are used.Type: GrantFiled: August 13, 2001Date of Patent: September 14, 2004Assignee: Genesis Group Inc.Inventor: James Edmund Wyse
-
Patent number: 6746867Abstract: The invention relates to a family of mammalian genes that are transcribed in the immediate early phase following exposure to Fibroblast Growth Factors (FGF) during mesoderm induction, termed Mesoderm Induction Immediate Early Response (MIER) genes. Defining features of the members of this family include that these genes are a) transcribed in response to fibroblast growth factors (FGF); b) are expressed within 40 minutes of FGF treatment; and c) do not require protein synthesis for transcription. There are at least eleven members within this family. The invention relates generally to compositions of and diagnostic methods relating to the M-MIER gene family, cDNA, nucleotide fragments, polypeptides coded thereby, recombinant host cells and vectors containing M-MIER encoding polynucleotide sequences, recombinant M-MIER polypeptides, and antibodies. By way of example, the invention discloses the cloning and functional expression of different M-MIER polypeptides.Type: GrantFiled: October 13, 1998Date of Patent: June 8, 2004Assignee: Genesis Group Inc.Inventors: Laura Lee Gillespie, Gary David Paterno